Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 18-F RDG-K5
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
[F-18] RGD-K5 Positron Emission Tomography (PET) in Participants With Carotid Artery Stenosis
Details : 18-F RDG-K5 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carotid Stenosis.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
May 21, 2012
Lead Product(s) : 18-F RDG-K5
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 18-F HX4
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Fudan University
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Evaluation of the New Hypoxia Imaging Agent HX4
Details : 18-F HX4 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Head and Neck Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
October 01, 2010
Lead Product(s) : 18-F HX4
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Fudan University
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors
Details : 18-F HX4 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Head and Neck Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
February 25, 2010
Reset All
